bims-nakice Biomed News
on Natural killer cells
Issue of 2026–11–15
eleven papers selected by
Santosh Phuyal, Oslo Universitetssykehus



  1. Nat Cancer. 2026 Nov 10.
      Emerging evidence positions natural killer (NK) cells as key initiators of the inflammatory programs required for effective tumor immunity. Beyond direct tumor killing, NK cells trigger early immune responses by recruiting and activating dendritic cells (DCs), thereby enabling downstream T cell activation. However, in established tumors, NK cell-DC communication is often disrupted by metabolic stress and immunosuppressive pathways, leading to immune evasion. Here, we review advances in NK cell-DC cross-talk, cytokine-driven amplification loops and metabolic control of NK cell fitness. We propose that restoring these integrated immune 'circuits' may be key in converting immune-excluded tumors into immunotherapy-responsive states.
    DOI:  https://doi.org/10.1038/s43018-026-01276-2
  2. Cell Death Discov. 2026 Aug 13. pii: 449. [Epub ahead of print]12(1):
      The majority of patients with colorectal cancer (CRC) fail to respond to anti-PD-1/PD-L1 immunotherapy, highlighting an urgent need for alternative immunotherapeutic targets. The immunosuppressive ligand CD155 potently dampens natural killer (NK) cell cytotoxicity via inhibitory receptors, but how CRC cells sustain high CD155 surface levels remains elusive. Here, we identify aberrant CD155 N-glycosylation as a critical driver of CRC immune evasion. We find that the glycosyltransferase STT3A contributes to N-glycosylation of CD155. This modification is essential for maintaining CD155 protein stability, thereby sustaining its surface expression to suppress NK cell-mediated antitumor immunity. Consistent with a role for N-glycosylation in maintaining CD155 expression, pharmacological inhibition of oligosaccharyltransferase activity with NGI-1 promotes CD155 turnover, effectively abrogating its immunosuppressive function and enhancing NK cell-mediated tumor clearance in vivo. Collectively, these findings implicate the STT3A-CD155 glycosylation axis as a therapeutic vulnerability, providing a mechanistic rationale for reprogramming the immunosuppressive CRC microenvironment.
    DOI:  https://doi.org/10.1038/s41420-026-03302-9
  3. J Immunol. 2026 Nov 02. pii: vkag313. [Epub ahead of print]215(11):
      Recently, primary natural killer (NK) cells have been engineered to express a transgenic T-cell receptor (NK:TCR), enabling recognition of intracellular and extracellular tumor antigens via HLA-restricted presentation. While this strategy broadens antigen specificity, NK cells lack canonical co-stimulatory receptors required for optimal T-cell activation. In T cells, CD28 engagement with CD80 and CD86 provides the essential "signal 2" that drives proliferation, differentiation, and cytokine production. We therefore examined whether expression of wild-type CD28 could facilitate co-stimulatory function to NK:TCR cells. Wild-type CD28 was introduced into NK-92 NFAT reporter cells and primary NK cells to assess its activity in the absence of TCR signaling. In parallel, CD28 was co-expressed with either relevant or irrelevant TCRs to evaluate its role in TCR-mediated responses. Our results show that CD28 signaling in NK cells differs from its role in T cells. CD28 functioned as a primary activating receptor, inducing activation upon interaction with CD80 or CD86 even in the absence of TCR engagement, resulting in the lysis of CD80- and/or CD86-positive cells, including antigen-presenting cells. This effect required the intracellular signaling domain of CD28. Blocking experiments demonstrated that both CD80 and CD86 are sufficient to drive activation, with no evidence for additional ligands. Notably, the presence of an irrelevant TCR did not restrain CD28-driven activation. These findings reveal fundamental differences in CD28-mediated signaling between NK and T cells and highlight a potential safety concern for NK-based therapies, as full-length CD28 expression may promote TCR-independent activation and cytotoxicity toward CD80/CD86-expressing cells.
    Keywords:  CD28; NK; cancer; co-stimulation; immunotherapy
    DOI:  https://doi.org/10.1093/jimmun/vkag313
  4. Cell Immunol. 2026 Nov 04. pii: S0008-8749(26)00108-5. [Epub ahead of print]430 105167
      Natural killer (NK) cells are innate lymphocytes that exert cytotoxic activity against malignant and virus-infected cells without prior antigen sensitization. Chimeric antigen receptor (CAR)-engineered NK (CAR-NK) cells combine CAR-dependent tumor-antigen recognition with endogenous NK-cell receptor-dependent cytotoxicity against stress-induced ligands and tumor cells with reduced HLA class I expression. Clinical studies of allogeneic CD19 CAR-NK cells have reported antitumor responses without notable cytokine release syndrome, neurotoxicity, or graft-versus-host disease. CAR-NK cells also support allogeneic manufacturing for off-the-shelf cellular therapy. NK-associated intracellular domains including DAP10, DAP12, 2B4, and CD3ζ, cytokine expression using IL-15 or IL-21, and gene editing of inhibitory molecules have been incorporated into CAR-NK designs. PI3K-AKT-mTORC1 and JAK-STAT signaling, glycolytic metabolism, mitochondrial activity, and transcriptional control contribute to CAR-NK cytotoxic function. Recent CAR-NK studies have also examined inhibitory-receptor editing, chemokine receptor expression, and metabolic engineering to improve cytotoxic activity, intratumoral infiltration, and resistance to hypoxia and immunosuppressive signaling in solid tumors. This review examines the molecular mechanisms involved in NK-cell activation and metabolism and evaluates molecular engineering strategies for next-generation CAR-NK therapy in solid tumors.
    Keywords:  CAR-NK cells; Cytokine engineering; Metabolic regulation; NK-specific signaling; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.cellimm.2026.105167
  5. Front Pharmacol. 2026 ;17 1952429
      Induced pluripotent stem cells (iPSCs) provide a scalable platform for off-the-shelf immune cell therapies; however, the mechanisms controlling maturation and functional specialization of iPSC-derived natural killer (iNK) cells are not fully understood. In this study, we combined single-cell transcriptomics, phenotypic profiling, and functional assays to characterize iNK cells and to determine whether temporally controlled expression of the transcription factor T-BET (TBX21) can promote iNK terminal specification and effector functions. Single-cell RNA sequencing and phenotypic profiling confirmed that baseline iNK cells form a transcriptionally distinct NK population and retain a developmental transcriptional signature. These iNK cells exhibited incomplete terminal maturation compared with peripheral blood NK cells, expressing much of the cytotoxic machinery but displaying limited acquisition of maturation-associated receptors. Despite induction of selected terminal specification markers, T-BET did not shift iNK cells toward a peripheral NK-like transcriptional identity. Instead, T-BET selectively triggered an inflammatory effector program characterized by elevated CCL3, CCL5 and GZMA expression and increased IFNγ production across multiple tumor targets, without enhancement of terminal cytotoxic gene programs. These findings suggest a functional dissociation between inflammatory and cytotoxic programs in iPSC-derived NK cells. This work highlights transcriptional engineering as a strategy to modulate functional state in stem cell-derived NK cells.
    Keywords:  NK cell maturation; T-BET (TBX21); iPSC differentiation; immunotherapy; induced pluripotent stem cells (iPSCs); inflammatory programming; natural killer cells (NK cells); off-the-shelf NK cells
    DOI:  https://doi.org/10.3389/fphar.2026.1952429
  6. Trends Cell Biol. 2026 Nov 07. pii: S0962-8924(26)00212-6. [Epub ahead of print]
      Beyond identifying individual malignant hallmarks, the central challenge in cancer biology is to uncover the fundamental organizing principles that underlie the interactive nature of cancer cell behavior. Here, we transform the ancient Wuxing theory into a mechanistically grounded, hypothesis-generating biological framework that conceptualizes cancer cell biology around five mutually interacting processes: Pliability, Hybridity, Aggressivity, Sociability, and Evolutivity (PHASE). By engaging in the circuit of mutual promotion and restriction, these phases form an integrated regulatory system that provides a rationale for organizing diverse malignant properties. Within this framework, cancer traits emerge as context-dependent manifestations of the proposed core interactions. Collectively, PHASE offers a complementary perspective for understanding disease progression that could advance interaction-guided therapeutic strategies to target human cancers.
    Keywords:  PHASE; biological processes; cancer hallmarks; cancer therapy; mutual interaction
    DOI:  https://doi.org/10.1016/j.tcb.2026.10.006
  7. Adv Sci (Weinh). 2026 Nov 09. pii: e78759. [Epub ahead of print]
      Solid tumor hypoxia is a major barrier to NK cell-based immunotherapy. To address this challenge, we establish a hypoxic preconditioning (HPC) model. We find that acute hypoxia (AH; 1% O2) significantly impairs NK92 cell cytotoxicity-such as granzyme B secretion and infiltration into lung cancer cell spheroids. In contrast, HPC pretreatment (gradual reduction from 5% to 1% O2) remarkably restores these functions. Mechanistically, transcriptomic analysis reveals that HPC markedly attenuates hypoxia -induced aberrant MAPK pathway activation. MAPK attenuation under normoxia recapitulates HPC -like protection by promoting mitochondrial biogenesis and metabolic remodeling, thereby enhancing the antitumor activity of NK92 cells both in vitro and in vivo. Notably, systemic MAPK inhibitor injection increases NKp46 expression on endogenous NK cells in BALB/c mice. Importantly, this strategy is also effective in human induced pluripotent stem cell (hiPSC)-derived induced NK (iNK) cells, supporting broader evaluation across NK cell platforms. Collectively, this study identifies the MAPK-mitochondrial metabolic axis as a critical regulator of hypoxia-induced NK cell dysfunction and proposes metabolic preconditioning as a strategy to overcome solid tumor hypoxia.
    Keywords:  MAPK signaling; hypoxic preconditioning; mitochondrial metabolism; natural killer cells; solid tumor immunotherapy
    DOI:  https://doi.org/10.1002/advs.78759
  8. STAR Protoc. 2026 Nov 10. pii: S2666-1667(26)00591-5. [Epub ahead of print]7(4): 104938
      Adeno-associated vector is a platform of choice for delivering genome-editing toolkits, due to its transient and robust expression. Here, we present a protocol for viral production for in vivo use. We describe steps for transfecting producer cells, harvesting virus, and purifying/concentrating viral particles. We then detail procedures for estimating viral titers. This protocol ensures high viral yields and transduction competency and is scalable to meet user-customized production needs. For complete details on the use of this protocol, please refer to Kantor et al.1.
    Keywords:  CRISPR; Cell Biology; Cell culture; Cell-based Assays; Genetics; Genomics; Molecular Biology; Protein Biochemistry
    DOI:  https://doi.org/10.1016/j.xpro.2026.104938
  9. bioRxiv. 2026 Oct 20. pii: 2026.10.19.760176. [Epub ahead of print]
      The endoplasmic reticulum is a major hub of protein synthesis, modification and trafficking that relies on the Unfolded Protein Response (UPR) to balance its folding capacity. IRE1, the most conserved of the UPR sensors, undergoes a change in oligomeric state upon activation that propagates the stress signal from the ER lumen to its cytoplasmic kinase/RNase domains. Here we show that opposing inputs from unfolded proteins and the ER chaperone machinery govern a dynamic cycle of IRE1 assembly. A bona fide unfolded ER client directly binds the IRE1 lumenal domain (LD) and promotes higher-order oligomerization. Model peptides further reveal that full assembly into LD filaments depends on ligand length, sequence, and IRE1's oligomerization interfaces. The ER Hsp70, BiP, counterbalances this process through two distinct mechanisms: i) an ATP-independent interaction via BiP's nucleotide-binding domain buffers early IRE1 assembly by engaging its oligomerization interface, whereas ii) ATP-regulated BiP/ERDJ machinery actively dismantles assembled filaments. Together, our findings reconcile direct unfolded protein recognition with BiP-mediated regulation to establish LD oligomerization as a point of integration through which unfolded protein load and chaperone availability dynamically regulate IRE1 assembly state and signalling.
    DOI:  https://doi.org/10.64898/2026.10.19.760176
  10. Methods Mol Biol. 2027 ;3099 87-104
      Prime editing (PE) is a precision genome-editing technology that allows all types of editing, such as substitutions, insertions, and deletions, at the target site in the genome of a cell without double-strand breaks (DSBs) or donor DNA. However, the targeting range of existing prime editing systems is limited due to their dependence on the NGG protospacer adjacent motif (PAM) recognized by Streptococcus pyogenes Cas9 (spCas9). To address this limitation, we have engineered prime editor variants incorporating PAM-flexible Cas9 proteins. These variants significantly expand the range of targetable genomic sites, allowing for the introduction of mutations previously inaccessible to standard editing methods. Here, we provide detailed methods for applying these PAM-flexible PE variants in human cell lines.
    Keywords:  CRISPR-Cas9; Genome engineering; PAM-flexible; Prime editing; pegRNA
    DOI:  https://doi.org/10.1007/978-1-0716-5667-9_7
  11. Front Immunol. 2026 ;17 2001812
      Immune-checkpoint blockade has improved outcomes in triple-negative breast cancer (TNBC), but resistance remains common. Natural killer (NK) cells provide complementary surveillance when classical major histocompatibility complex class I (MHC-I) expression is lost or heterogeneous. HLA-E can inhibit NK cells and subsets of CD8+ T cells through CD94/NKG2A, but can also engage activating CD94/NKG2C. In breast cancer, HLA-E associations depend on classical MHC-I status, while spatial TNBC studies link MHC-I heterogeneity to NKG2A-mediated resistance in experimental models. Evidence varies by subtype and remains predominantly translational; clinical efficacy of NKG2A blockade has not been established, including in the small MIMOSA trial of HER2-positive disease. This Mini Review evaluates breast cancer-specific and cross-tumor evidence, the NKG2A/NKG2C balance, therapeutic combinations, and practical biomarker development. We propose prospective assessment of tumor-cell surface HLA-E, regional MHC-I status, NKG2A-positive effectors, activating-receptor balance, and spatial proximity rather than HLA-E positivity alone.
    Keywords:  HLA-E; NKG2A; breast cancer; immune checkpoint; immunotherapy; monalizumab; natural killer cells; triple-negative breast cancer
    DOI:  https://doi.org/10.3389/fimmu.2026.2001812